Histone methyltransferase Prmt1 in normal development and cancer therapeutics. (360G-Wellcome-087368_Z_08_Z)
Prmtl has emerged as a critical factor for both transcriptIonal regulation and leukemogenesis, the objective of this project is to characterize the roles of Prmtl in hematopoietlc development. I reason that comprehensive analysis of the loss of function of Prmtl in hematopoietic stem cells (HSCs) and/or progenitors during different developmental stages will give important Insights into the normal functions of Prmtl, which will also provide crucial Information for development of strategies targeting Prmtl in human diseases.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 272566 |
| Applicant Surname | Holmes |
| Approval Committee | Neurosciences And Mental Health |
| Award Date | 2008-09-16T00:00:00+00:00 |
| Financial Year | 2007/08 |
| Grant Programme: Title | PhD Studentship (Basic & Clinical) |
| Internal ID | 087368/Z/08/Z |
| Lead Applicant | Ms Katherine Holmes |
| Partnership Value | 272566 |
| Planned Dates: End Date | 2012-09-30T00:00:00+00:00 |
| Planned Dates: Start Date | 2008-10-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Greater London |
| Sponsor(s) | Prof Paul Workman |